Pluristem Therapeutics (PSTI) Says U.S. FDA Cleared its Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery
Tweet Send to a Friend
Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
